Genetic mutations in the <i>EGFR</i>, <i>TP53</i> and <i>CDKN2A</i> genes were also analyzed.<h4>Methods</h4>Kaplan-Meier survival analysis was used to assess the impact of clinical, tumor-related, treatment, lifestyle and genetic variables on overall survival and progression-free survival, with group differences evaluated using log-rank tests. The gene discussed is CDKN2A; the disease is neoplasm.